This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Robert F. Coniff, MD; Jo Ann Shapiro, MS; Timothy B. Seaton, MD

Arch Intern Med. 1994;154(21):2442-2448.

Abstract
Background
Acarbose delays the release of glucose from complex carbohydrates and disaccharides by inhibiting intestinal -glucosidases, attenuating postprandial increments in blood glucose and insulin. This multicenter double-blind study compared the efficacy and safety of acarbose with placebo in the treatment of obese subjects with non—insulin-dependent diabetes mellitus (NIDDM) managed by diet.

Methods
Two hundred twelve obese subjects with NIDDM who had not received any diabetic medication for at least 12 weeks were randomized to receive acarbose or placebo. The subjects were stratified by fasting glucose level above or below 11.1 mmol/L (200 mg/dL). Based on the subject's therapeutic response and tolerance, the acarbose dosage was titrated from 50 to 300 mg three times per day. This 36-week study consisted of a 6-week pretreatment period, a 24-week double-blind treatment period, and a 6-week posttreatment period.

Results
Ninety-one subjects given acarbose and 98 subjects who received placebo were evaluable for efficacy. During a standard meal tolerance test at the double-blind end point, the differences between treatment groups in mean change from baseline were as follows: 0.9 mmol/L (16 mg/dL) for fasting plasma glucose level, approximately 2.8 mmol/L (50 mg/dL) for postprandial plasma glucose level, and 0.59% (P<.0001) for hemoglobin A1c concentration (for all three measurements, values decreased in the acarbose group and increased in the placebo group).

Conclusions
Acarbose improved both fasting and 2postprandial hyperglycemia and improved overall glycemic control as measured by the hemoglobin A_1c level. These findings suggest a beneficial role for acarbose in combination with diet in the treatment of obese subjects with NIDDM.

(Arch Intern Med. 1994;154:2442-2448)

Author Affiliations
From the Department of Metabolics, Pharmaceutical Division, Miles Inc, West Haven, Conn.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

{alpha}-Glucosidase Inhibitors for Patients With Type 2 Diabetes: Results from a Cochrane systematic review and meta-analysis
van de Laar et al.
Diabetes Care 2005;28:154-163.
ABSTRACT | FULL TEXT  

Oral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review
Inzucchi
JAMA 2002;287:360-372.
ABSTRACT | FULL TEXT  

Pathophysiology and Pharmacological Treatment of Insulin Resistance
Matthaei et al.
Endocr. Rev. 2000;21:585-618.
ABSTRACT | FULL TEXT  

Changes of Fermentation Pathways of Fecal Microbial Communities Associated with a Drug Treatment That Increases Dietary Starch in the Human Colon
Wolin et al.
Appl. Environ. Microbiol. 1999;65:2807-2812.
ABSTRACT | FULL TEXT  

Acarbose Enhances Human Colonic Butyrate Production
Weaver et al.
J. Nutr. 1997;127:717-723.
ABSTRACT | FULL TEXT